Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Return on Equity (2022 - 2025)

Historic Return on Equity for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to 0.66%.

  • Phathom Pharmaceuticals' Return on Equity fell 9500.0% to 0.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.66%, marking a year-over-year decrease of 9500.0%. This contributed to the annual value of 2.05% for FY2024, which is 6800.0% down from last year.
  • Phathom Pharmaceuticals' Return on Equity amounted to 0.66% in Q3 2025, which was down 9500.0% from 0.89% recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Return on Equity registered a high of 2043.99% during Q3 2023, and its lowest value of 0.66% during Q3 2025.
  • For the 4-year period, Phathom Pharmaceuticals' Return on Equity averaged around 172.45%, with its median value being 1.92% (2024).
  • Its Return on Equity has fluctuated over the past 5 years, first soared by 5500bps in 2023, then crashed by -20423800bps in 2024.
  • Phathom Pharmaceuticals' Return on Equity (Quarter) stood at 3.9% in 2022, then grew by 14bps to 4.45% in 2023, then tumbled by -66bps to 1.52% in 2024, then plummeted by -56bps to 0.66% in 2025.
  • Its Return on Equity stands at 0.66% for Q3 2025, versus 0.89% for Q2 2025 and 1.17% for Q1 2025.